Bone metastasis represents one of the most critical challenges in cancer management, often remaining undetected until advanced stages due to its asymptomatic progression. Recent insights reveal that microRNAs (miRNAs), small noncoding RNA molecules, are emerging as pivotal regulators in the metastatic spread of cancer to bone. Unlike traditional protein-coding gene profiles, miRNA expression signatures offer enhanced sensitivity and specificity in early tumor and metastasis detection. Certain miRNAs such as miR-21, miR-10b, and miR-218-5p have been identified as pro-metastatic agents in breast cancer, promoting osteoclastogenesis, extracellular matrix modeling, and tumor microenvironment modulation. Notably, miRNAs also influence osteoblast and osteoclast activity, thereby contributing to bone remodeling imbalances and facilitating metastatic colonization. The dual role of miRNAs as both oncogenic drivers and tumor suppressors positions them as promising diagnostic and therapeutic tools. For instance, miR-34a, currently under clinical trial as liposomal mimic, demonstrates potential in halting bone metastasis by suppressing Notch signaling and osteoclast differentiation. Furthermore, the unique presence and stability of circulating miRNAs in blood make them viable candidates for noninvasive biomarkers. Collectively, these findings underscore the transformative role of miRNAs in understanding and combating bone metastasis, offering new hope for early detection and personalized therapy in metastatic cancers.